Press releases
- Press releases
- Browse
Press releases
GenOdyssee S.A. announced today that the Journal of antimicrobial Agents and Chemotherapy (AAC*), has accepted a manuscript describing stronger and more sustained inhibitory effect of GenOdyssee's lead antiviral drug candidate, GEA007.1 More
Data describing the higher antiviral potency of GenOdyssee's lead antiviral IFN alpha variant GEA007.1 compared to IFN alpha 2b, against HCV replication, will be presented in Paris, at the International Symposium on Viral Hepatitis and Liver Disease More
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor More
Related Reports
Market Research Reports provided by reports.iptechex.com
Mar 2011 - 20 pages - $250
Jan 2011 - 99 pages - $3,835
Aug 2010 - 80 pages - $1,215
Sep 2009 - 167 pages - $4,650
Dec 2010 - 124 pages - $3,500
Mar 2011 - 14 pages - $750
Sep 2010 - 21 pages - $99
Aug 2010 - 138 pages - $1,215
Sep 2009 - 266 pages - $3,835
Nov 2010 - 311 pages - $4,650
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us